TY - JOUR
T1 - Weekly paclitaxel in heavily pretreated ovarian cancer patients
T2 - Does this treatment still provide further advantages?
AU - Miolo, Gianmaria
AU - Bidoli, Ettore
AU - Lombardi, Davide
AU - Santeufemia, Davide Adriano
AU - Capobianco, Giampiero
AU - Dessole, Francesco
AU - Scalone, Simona
AU - Spazzapan, Simon
AU - Sorio, Roberto
AU - Tabaro, Gianna
AU - Veronesi, Andrea
PY - 2012/2
Y1 - 2012/2
N2 - Objective To evaluate the disease control rate (DCR) in heavily pretreated and relapsed ovarian cancer patients re-challenged with a weekly paclitaxel schedule and to establish whether a correlation between dose intensity, progression-free interval (PFI) and overall survival (OS) exists. Methods Retrospective data were collected from 30 heavily pretreated metastatic ovarian cancer patients who received 80 mg/m2/week paclitaxel regimen. Results The treatment was well tolerated and showed a DCR in 70% of the patients, with only one case of grade 3 hematological toxicity. One patient (3%) showed a complete response, 15 patients (50%) a partial response and five patients (17%) a stabilization of their disease. The regimen was mostly used as a fourth-line chemotherapy (range 2-7). The median dose intensity in responding patients was 57.5 mg/m2/week and in those with progressive disease 49.7 mg/m2/week. (p = 0.20). PFI and OS were increased in the responder patient groups with a log-rank test of 25.64 (p <0.001) and 15.10 (p = 0.0001), respectively. Conclusions Weekly administration of paclitaxel was active and well tolerated as a salvage therapy for heavily pretreated ovarian cancer patients.
AB - Objective To evaluate the disease control rate (DCR) in heavily pretreated and relapsed ovarian cancer patients re-challenged with a weekly paclitaxel schedule and to establish whether a correlation between dose intensity, progression-free interval (PFI) and overall survival (OS) exists. Methods Retrospective data were collected from 30 heavily pretreated metastatic ovarian cancer patients who received 80 mg/m2/week paclitaxel regimen. Results The treatment was well tolerated and showed a DCR in 70% of the patients, with only one case of grade 3 hematological toxicity. One patient (3%) showed a complete response, 15 patients (50%) a partial response and five patients (17%) a stabilization of their disease. The regimen was mostly used as a fourth-line chemotherapy (range 2-7). The median dose intensity in responding patients was 57.5 mg/m2/week and in those with progressive disease 49.7 mg/m2/week. (p = 0.20). PFI and OS were increased in the responder patient groups with a log-rank test of 25.64 (p <0.001) and 15.10 (p = 0.0001), respectively. Conclusions Weekly administration of paclitaxel was active and well tolerated as a salvage therapy for heavily pretreated ovarian cancer patients.
KW - Chemotherapy
KW - Dose density
KW - Ovarian carcinoma
KW - Weekly paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=84864429842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864429842&partnerID=8YFLogxK
U2 - 10.1007/s00404-011-1976-9
DO - 10.1007/s00404-011-1976-9
M3 - Article
C2 - 21735184
AN - SCOPUS:84864429842
VL - 285
SP - 499
EP - 503
JO - Archives of Gynecology
JF - Archives of Gynecology
SN - 0170-9925
IS - 2
ER -